2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访

2023-09-05 欧洲肿瘤内科学会 Ann Oncol 发表于上海

指南主要内容涵盖了胰腺癌的诊断、分期,风险评估、治疗、疾病监测和随访。所有建议均基于现有的科学数据和集体专家意见。

中文标题:

2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访

英文标题:

Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

发布机构:

欧洲肿瘤内科学会

发布日期:

2023-09-05

简要介绍:

该指南涵盖诊断、分期、风险评估、治疗、疾病监测和随访。

多学科专家作者团队来自欧洲、亚洲和美国的不同机构和国家。

建议基于现有的科学数据和作者的集体专家意见。

ESMO-MCBS 和 ESCAT 评分为治疗选择(包括靶向治疗)提供了不同程度的证据。

在临床实践中,提供的所有建议都需要与患者以共同决策的方式进行讨论。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf)] GetToolGuiderByIdResponse(projectId=1, id=240451c003331954, title=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访, enTitle=Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, guiderFrom= Ann Oncol, authorId=0, author=, summary=指南主要内容涵盖了胰腺癌的诊断、分期,风险评估、治疗、疾病监测和随访。所有建议均基于现有的科学数据和集体专家意见。 , cover=https://img.medsci.cn/Random/busy-reception-in-a-hospital-with-doctors-and-PUPDEB8.jpg, journalId=0, articlesId=null, associationId=14, associationName=欧洲肿瘤内科学会, associationIntro=欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology )是1975年成立的非盈利组织,是欧洲领先的专业组织,致力于提高肿瘤内科的专业性,推进癌症治疗和护理的多学科诊疗方法。, copyright=0, guiderPublishedTime=Tue Sep 05 00:00:00 CST 2023, originalUrl=, linkOutUrl=, content=<p class="ce-list--remove-bullets__list-item__text">该指南涵盖诊断、分期、风险评估、治疗、疾病监测和随访。</p> <p class="ce-list--remove-bullets__list-item__text">多学科专家作者团队来自欧洲、亚洲和美国的不同机构和国家。</p> <p class="ce-list--remove-bullets__list-item__text">建议基于现有的科学数据和作者的集体专家意见。</p> <p class="ce-list--remove-bullets__list-item__text">ESMO-MCBS 和 ESCAT 评分为治疗选择(包括靶向治疗)提供了不同程度的证据。</p> <p class="ce-list--remove-bullets__list-item__text">在临床实践中,提供的所有建议都需要与患者以共同决策的方式进行讨论。</p>, tagList=[TagDto(tagId=718, tagName=胰腺癌)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=718, articleKeyword=胰腺癌, articleKeywordNum=6, guiderKeywordId=718, guiderKeyword=胰腺癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5712, appHits=142, showAppHits=0, pcHits=518, showPcHits=5570, likes=0, shares=27, comments=4, approvalStatus=1, publishedTime=Fri Sep 08 16:00:00 CST 2023, publishedTimeString=2023-09-05, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Fri Sep 08 13:41:32 CST 2023, updatedBy=8538692, updatedName=梅斯话题小助手, updatedTime=Sat Jan 06 09:06:50 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=上海, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf)])
2023 ESMO临床实践指南:胰腺癌的诊断、治疗和随访.pdf
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
    2023-10-09 苏日娜 来自内蒙古

    感谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2163067, encodeId=789a216306e87, content=<a href='/topic/show?id=5dab10e018a4' target=_blank style='color:#2F92EE;'>#乳腺癌诊断#</a><a href='/topic/show?id=415f10e0196f' target=_blank style='color:#2F92EE;'>#乳腺癌分期#</a><a href='/topic/show?id=1cfb23e6157' target=_blank style='color:#2F92EE;'>#乳腺癌治疗#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=107018, encryptionId=5dab10e018a4, topicName=乳腺癌诊断), TopicDto(id=107019, encryptionId=415f10e0196f, topicName=乳腺癌分期), TopicDto(id=23761, encryptionId=1cfb23e6157, topicName=乳腺癌治疗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Mon Oct 16 14:00:46 CST 2023, time=2023-10-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2161794, encodeId=1e632161e948e, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=570e6483876, createdName=苏日娜, createdTime=Mon Oct 09 19:19:31 CST 2023, time=2023-10-09, status=1, ipAttribution=内蒙古), GetPortalCommentsPageByObjectIdResponse(id=2156830, encodeId=f5d6215683054, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJibu7hwJqpmHiaJgLLmJmcwp0WDTxWI3vqPBO1Mloq21VBOPqziapyibYatvd2QWHWicolL1vbVZHgpRQ/132, createdBy=d16a2107341, createdName=JZ Yang, createdTime=Sat Sep 09 07:24:58 CST 2023, time=2023-09-09, status=1, ipAttribution=浙江省)]
    2023-09-09 JZ Yang 来自浙江省

    感谢分享

    0

拓展阅读

Nat Commun:中南大学金鑫/华中科技大学江科/唐露发现KRAS加速胰腺癌进展的新机制

该研究使用KPC小鼠模型来探索棕榈酰化对胰腺癌进展的影响。KRAS上调诱导ZDHHC20在胰腺癌患者中异常过表达,与胰腺癌患者的预后不良相关。

JCO:北京大学齐长松团队发现CAR-T细胞疗法让胰腺癌实体瘤患者获益

该研究报告了两项探索性临床试验的汇总分析结果,以评估CT041在既往治疗过的胰腺癌(PC)患者中的作用。

Genes & Diseases:Mo YY/Yang L/Peng WX教授团队揭示LINC00901促进胰腺癌发展

文章报道了长链非编码RNA(lncRNA) LINC00901在胰腺癌的发生、发展中起重要的促进作用,并受到m6A修饰调控。

指南更新 | 胰腺癌NCCN(2024.V2):首次针对HER2阳性患者新增德曲妥珠单抗方案!

此次更新的主要内容为诊疗流程新增通过免疫组化检测HER2过表达;局部进展期/转移性疾病的后续治疗和复发疾病的治疗,体能状态评分良好0-1,新增德曲妥珠单抗。

European Radiology:MRI+DWI提高了胰腺癌肝转移的检测和手术候选人的选择

随着成像技术的提高和肝胆对比剂的可获得性的提高,近年来的研究报道了磁共振成像 (MRI)在肝肿瘤术前评估中的优越性。

特别关注|胰腺癌动物模型的比较与选择

本文将对各种常用的PC动物模型进行比较,旨在为PC研究中动物模型的选择提供一定的依据。

2010ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2010-05-01

胰腺癌诊疗规范(2011年版)

中华人民共和国卫生部(MINISTRY OF HEALTH OF THE PEOPLE`S REPUBLIC OF CHINA) · 2011-10-14

2012 胰腺癌经动脉灌注化疗指南(草案)

中华医学会放射学分会介入学组 · 2012-05-30

2012 ESMO临床实践指南:胰腺癌

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2012-06-01

2013 胰腺癌多学科综合治疗协作组专家共识

中华医学会肿瘤学分会 · 2013-05-01